Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Urologic ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Screening for prostate cancer—the controversy that refuses to die.N Engl J Med. 2009; 360: 1351-1354
- Prostate cancer screening: the need for problem-solving that puts men's interests first.Eur Urol. 2009; 56: 34-37
- Screening for prostate cancer: U.S. preventive services task force recommendation statement.Ann Intern Med. 2008; 149: 185-191
- PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial.N Engl J Med. 2009; 360 (Erratum in: N Engl J Med 2009 Apr 23;360(17):1797): 1310-1319
- ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study.N Engl J Med. 2009; 360: 1320-1328
Horner MJ, Ries LAG, Krapcho M, et al, editors. SEER Cancer statistics review, 1975–2006. Bethesda (MD): National Cancer Institute. Table 23.9: cancer of the prostate. Available at: http://seer.cancer.gov/csr/1975_2006/index.html. Accessed October 15, 2009.
- Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden.BJU Int. 2000; 85: 1078-1084
- Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.J Natl Cancer Inst. 2008; 100: 1144-1154
- Quality of life of men treated for localized prostate cancer: outcomes at 6 and 12 months.Support Care Cancer. 2009; 17: 509-517
- The psychological aftermath of prostate cancer treatment choices: a comparison of depression, anxiety and quality of life outcomes over the 12 months following diagnosis.Med J Aust. 2009; 190: S86-S89
- Quality-of-life outcomes in men treated for localized prostate cancer.JAMA. 1995; 273: 129-135
- Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer.Cancer. 2007; 109: 2239-2247
- Quality of life and satisfaction with outcome among prostate-cancer survivors.N Engl J Med. 2008; 358: 1250-1261
- Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.Eur Urol. 2009; 55: 422-430
- Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.J Natl Cancer Inst. 2009; 101: 374-383
- Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005.J Natl Cancer Inst. 2009; 101: 1325-1329
- Characteristics of prostate cancer detected by digital rectal examination only.Urology. 2007; 70: 1117-1120
- The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.Eur Urol. 2008; 54: 581-588
- Adenocarcinoma of the prostate: results of routine urological screening.J Urol. 1984; 132: 690-692
- Importance of peripheral biopsies in maximizing the detection of early prostate cancer in repeat 12-core biopsy protocols.BJU Int. 2006; 98: 559-562
- Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation.Urology. 2007; 70: 1131-1135
- Saturation technique does not improve cancer detection as an initial prostate biopsy strategy.J Urol. 2006; 175: 485-488
- Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.JAMA. 2005; 294: 66-70
- Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter.N Engl J Med. 2004; 350: 2239-2246
- Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program.Urology. 2002; 60: 826-830
- Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study [review].J Urol. 2001; 166: 856-860
- Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence.J Natl Cancer Inst. 2007; 99: 1484-1489
- Contrast-enhanced transrectal ultrasound (CE-TRUS) with cadence-contrast pulse sequence (CPS) technology for the identification of prostate cancer.Urol Oncol. 2009; ([Epub ahead of print])
- Prostate cancer detection: the value of performing an MRI before a biopsy.Acta Radiol. 2009; 50: 1080-1088
- Prostate cancer: current evidence weighs against population screening.CA Cancer J Clin. 2009; 59: 220-224
- Bureau, statistical abstract of the United States: 2009.(128th edition). 2008 (Washington, DC; 2008. Table 103: expectation of life and expected deaths by race, sex, and age: 2005. Available at:) (Accessed October 10, 2009)
- Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: implications for screening recommendations.Int J Radiat Oncol Biol Phys. 2009; ([Epub ahead of print])
- Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort.J Clin Oncol. 2009; 27: 4980-4985
Article info
Identification
Copyright
© 2010 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
